Tonix Pharmaceuticals Holding Corp (TNXP)
0.146
+0.01
(+6.88%)
USD |
NASDAQ |
Sep 27, 16:00
0.145
0.00 (0.00%)
After-Hours: 20:00
Tonix Pharmaceuticals SG&A Expense (Annual): 34.75M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 34.75M |
| December 31, 2022 | 30.22M |
| December 31, 2021 | 23.47M |
| December 31, 2020 | 14.35M |
| December 31, 2019 | 10.64M |
| December 31, 2018 | 8.764M |
| December 31, 2017 | 7.949M |
| December 31, 2016 | 10.44M |
| Date | Value |
|---|---|
| December 31, 2015 | 12.66M |
| December 31, 2014 | 9.039M |
| December 31, 2013 | 6.238M |
| December 31, 2012 | 4.078M |
| December 31, 2011 | 2.220M |
| December 31, 2010 | 1.344M |
| December 31, 2009 | 0.0139M |
| December 31, 2008 | 0.014M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
10.64M
Minimum
2019
34.75M
Maximum
2023
22.69M
Average
23.47M
Median
2021
SG&A Expense (Annual) Benchmarks
| Emergent BioSolutions Inc | 368.40M |
| Geovax Labs Inc | 6.022M |
| Abbott Laboratories | 10.95B |
| SIGA Technologies Inc | 22.04M |
| Chimerix Inc | 24.60M |